AsclepiX Therapeutics
AsclepiX Therapeutics is a Baltimore-based, clinical-stage biotech developing AXT107, a peptide therapeutic designed via computational biology for wet AMD and other neovascular retinal diseases. Pre-revenue and venture-backed, the company is advancing its lead candidate through a Phase 1/2a trial.
- Company typePrivate
- Founded2011
- HeadquartersBaltimore, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
AsclepiX Therapeutics firmographics
Firmographics- Name
- AsclepiX Therapeutics
- Legal name
- AsclepiX Therapeutics, Inc.
- Website
- https://asclepix.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- AsclepiX Therapeutics is a Baltimore-based, clinical-stage biotech developing AXT107, a peptide therapeutic designed via computational biology for wet AMD and other neovascular retinal diseases. Pre-revenue and venture-backed, the company is advancing its lead candidate through a Phase 1/2a trial.
- Ownership category
- akta.pro rank
AsclepiX Therapeutics industry classification
Industry- Product category
- Ophthalmic Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL)
Keywords
Where AsclepiX Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Baltimore
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
AsclepiX Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain
Revenue model
- Drug Development and Commercialization: As a clinical-stage biotech company, AsclepiX Therapeutics is developing AXT107 for the treatment of neovascular retinal diseases including wet AMD. The company is pre-revenue and currently funded through venture capital. Future revenue will be generated through pharmaceutical product sales upon regulatory approval.
Go-to-market motion1 record
AsclepiX Therapeutics product offering
Product offeringCore offering
AsclepiX Therapeutics develops AXT107, a peptide-based therapeutic candidate designed via computational biology for the treatment of neovascular retinal diseases, with the primary focus on wet age-related macular degeneration (wet AMD). The company is currently advancing AXT107 through a Phase 1/2a clinical trial (DISCOVER study) to evaluate safety, tolerability, and efficacy. Beyond retinal disease, the company is also developing peptide therapeutics for cancer indications.
Differentiator
Problem solved
Functional benefit
Products and services
- AXT107 AXT107 is a peptide-based therapeutic candidate developed using computational biology approaches for the treatment of neovascular retinal diseases, with primary focus on wet age-related macular degeneration (wet AMD). It is currently being evaluated in the Phase 1/2a DISCOVER clinical study for safety, tolerability, and efficacy in patients with wet AMD.
Quantifiable outcome
- Phase 1/2a DISCOVER study initiated to evaluate safety, tolerability, and efficacy of AXT107 in wet AMD patients
Companies that use AsclepiX Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
AsclepiX Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
AsclepiX Therapeutics partnerships and signals
Strategic signalScale indicators3 records
AsclepiX Therapeutics competitors and assessment
Company assessmentDirect peers
- Clearside Biomedical: Clinical-stage biotech developing suprachoroidal drug delivery for retinal and choroidal diseases. Direct peer in ocular drug delivery and retinal therapeutics.
- REGENXBIO: Clinical-stage gene therapy company with ABBV-RGX-314 for wet AMD and diabetic retinopathy. Direct peer in retinal disease therapeutic development with novel modality.
- Ocular Therapeutix: Clinical-stage biotech developing sustained-release ocular therapeutics for retinal diseases and other eye conditions. Direct peer in the ophthalmology therapeutic space with similar stage and indication focus.
- Apellis Pharmaceuticals: Commercial-stage biotech with Syfovre for geographic atrophy and ongoing retinal disease programs. Direct peer in retinal therapeutics with a differentiated complement-cascade mechanism.
- EyePoint Pharmaceuticals: Clinical/commercial-stage company developing sustained-release ocular drug delivery (DURYSTA for glaucoma, pipeline in retinal diseases). Direct peer in ocular therapeutic delivery.
- Adverum Biotechnologies: Clinical-stage gene therapy company developing ADVM-022 (ixoberogene soroparvovec) for wet AMD. Direct peer in novel-modality retinal disease therapeutics.
- Kodiak Sciences: Clinical-stage biotech developing novel therapeutics for retinal diseases, including wet AMD and diabetic macular edema. Direct peer in retinal disease drug development with anti-VEGF alternative approaches.
- Iveric Bio: Retinal disease therapeutics developer (Izervay for geographic atrophy), acquired by Astellas in 2023. Direct peer in novel retinal therapeutics; provides benchmark exit valuation.
Emerging players
- Lineage Cell Therapeutics: Clinical-stage cell therapy company with OpRegen for dry AMD and other retinal programs. Emerging peer in advanced therapy approaches for retinal disease.
- Palatin Technologies: Clinical-stage biotech developing peptide therapeutics (including for ocular indications such as dry eye). Emerging peer based on peptide therapeutic modality rather than retinal disease focus.
Market position
Customer concentration
AsclepiX Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
AsclepiX Therapeutics leadership team
Management profileNumber of profiles
Profiles3 records
AsclepiX Therapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AsclepiX Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AsclepiX Therapeutics
What does AsclepiX Therapeutics do?
AsclepiX Therapeutics develops AXT107, a peptide-based therapeutic candidate designed via computational biology for the treatment of neovascular retinal diseases, with the primary focus on wet age-related macular degeneration (wet AMD). The company is currently advancing AXT107 through a Phase 1/2a clinical trial (DISCOVER study) to evaluate safety, tolerability, and efficacy. Beyond retinal disease, the company is also developing peptide therapeutics for cancer indications.
Is AsclepiX Therapeutics a public or private company?
AsclepiX Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was AsclepiX Therapeutics founded?
AsclepiX Therapeutics was founded in 2011. It employs 1 to 10 people.
Where is AsclepiX Therapeutics based?
AsclepiX Therapeutics is headquartered in Baltimore, United States, in the North America region.
How does AsclepiX Therapeutics make money?
One revenue line is on record: drug Development and Commercialization.
Who are AsclepiX Therapeutics's main competitors?
Direct peers on record are Clearside Biomedical, REGENXBIO, Ocular Therapeutix, Apellis Pharmaceuticals, EyePoint Pharmaceuticals, Adverum Biotechnologies, Kodiak Sciences and Iveric Bio. Emerging players are Lineage Cell Therapeutics and Palatin Technologies.
Does AsclepiX Therapeutics have an API?
No public API is recorded for AsclepiX Therapeutics.
What industry is AsclepiX Therapeutics in?
AsclepiX Therapeutics's product category is Ophthalmic Therapeutics. Its primary akta.pro industry code is HLAHAIAL, Ocular Drug Delivery Devices (Eye Droppers/Inserts). Its NAICS code is 541714 and its SIC code is 2834.